AZN Earnings Prediction
The chart below shows how AZN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AZN sees a -1.58% change in stock price 10 days leading up to the earnings, and a +1.21% change 10 days following the report. On the earnings day itself, the stock moves by +1.45%. This data can give you a slight idea of what to expect for the next quarter's release.
AZN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
13.56B
18.04%
4.85%
Gross Margin
81.83%
-0.24%
-1.62%
Operating Margin
24.69%
32.17%
1.73%
Net Margin
10.56%
-11.93%
-29.13%
EPS
0.91
3.41%
-26.61%
No Data Available
AZN Earnings Analysis
AstraZeneca PLC Corporation (AZN.O) Earnings Conference Call
Positive
Robust Revenue Increase: 1. Strong Revenue Growth: AstraZeneca reported a 21% increase in total revenue for Q3 2024, driven by robust global demand for its medicines.
Core EPS Surge: 2. Core EPS Increase: The company achieved a 27% rise in core EPS, reaching $2.08, reflecting a strong focus on profitability.
Alliance Revenue Surge: 3. Significant Alliance Revenue Growth: Alliance revenue surged by 50% to $1.5 billion, primarily due to increased sales of Enhertu and Tezspire.
U.S. Operations Investment: 4. Investment in U.S. Operations: AstraZeneca announced a $3.5 billion investment in U.S. manufacturing and R&D, highlighting its commitment to growth in this key market.
Oncology Revenue Surge: 5. Oncology Revenue Growth: Total oncology revenues grew by 22% to $16 billion in the first nine months of the year, driven by strong demand across various regions.
Negative
Net Debt Increase: 1. Increased Net Debt: AstraZeneca's net debt rose by $3.8 billion, primarily due to acquisitions and dividend payments, resulting in a net debt-to-EBITDA ratio of 1.8 times.
Declining Sales Margin: 2. Declining Product Sales Gross Margin: The company's core product sales gross margin is expected to decline in the fourth quarter, following a slight decrease in the third quarter compared to the first half of the year.
R&D Expense Increase: 3. R&D Expense Growth: Research and development expenses increased by 18% year-to-date, driven by the integration of recent acquisitions and accelerated R&D projects, indicating rising costs without immediate revenue return.
Impairment and Portfolio Challenges: 4. Impairment Charges: AstraZeneca incurred impairment and related charges for Andexxa as part of its regular portfolio prioritization, reflecting challenges in maintaining product value.
Increased Finance Expenses: 5. Higher Finance Expenses: Finance expenses are anticipated to be higher in 2024 compared to 2023 due to $6.5 billion in bond issuances at elevated interest rates, impacting overall profitability.
AZN FAQs
How does AZN typically perform around its earnings report dates?
Is AstraZeneca PLC (AZN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AZN Earning Call Sentiment
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AZN.O
1.48%Positive
The earnings call reveals strong revenue growth, but concerns about regulatory issues in China, competitive pressures, increased debt, and supply chain challenges offset the positives. The Q&A section highlights management's uncertainty about the impact of these issues, particularly in China, and vague responses to analyst queries. Despite upgraded guidance and record revenue, financial challenges and uncertainties lead to a neutral sentiment rating, with no clear indication of a strong positive or negative short-term stock movement.